Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

785.45 +5.78 (+0.74%)
Streaming Delayed Price Updated: 11:32 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
59 60 Next >
News headline image
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points ↗
Broadcom and Arista lead five stocks sporting a flat base. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
The Latest Analyst Ratings for Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Down 45%, Is Intellia a Buy? ↗
Intellia's operating in the high-growth field of gene editing. 
Via The Motley Fool
News headline image
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up ↗
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment. 
Via Talk Markets
News headline image
P/E Ratio Insights for Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. 
Via Talk Markets
News headline image
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This Market-Beating Stock Just Gave Investors More Reasons to Invest ↗
There is a lot going the way of this biotech giant right now. 
Via The Motley Fool
News headline image
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close) ↗
This stock puts the "big" in big pharma after massive gains in recent years. 
Via The Motley Fool
News headline image
Examining the Quality Attributes of NASDAQ:REGN. ↗
Why the quality investor may take a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN). 
Via Chartmill
News headline image
Analyst Expectations for Regeneron Pharmaceuticals's Future ↗
 
Via Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/19 Morning Trading
Via Investor Brand Network
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗
 
Via Benzinga
News headline image
MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer ↗
MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S. 
Via Benzinga
News headline image
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Stock Split Watch: Is Regeneron Pharmaceuticals Next? ↗
If the biotech does split its stock, it will be a first for the company. 
Via The Motley Fool
News headline image
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Three Of Our Top Picks For Your Healthcare Portfolio ↗
Amidst macro uncertainty, healthcare stocks should outperform. 
Via Talk Markets
News headline image
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
News headline image
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost ↗
A higher-dose version of Eylea will help the company fight off competition and increase revenue. 
Via The Motley Fool
News headline image
3 Stocks to Buy to Ride Europe’s Coming Market Surge ↗
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave. 
Via InvestorPlace
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.